Region:Europe
Author(s):Geetanshi
Product Code:KRAA3691
Pages:81
Published On:September 2025
By Type:The market can be segmented into various types, including diagnostic testing, therapeutic applications, research and development services, genetic counseling, bioinformatics solutions, genomic data management, pharmacogenomics services, and others. Each of these segments plays a crucial role in the overall growth of the market. Diagnostic testing (such as next-generation sequencing, PCR, and microarray) and therapeutic applications (including targeted therapies and gene therapy) are particularly significant, as they directly impact patient care, enable early disease detection, and support the development of individualized treatment strategies. The growing adoption of bioinformatics and genomic data management solutions further enhances the efficiency and scalability of personalized medicine initiatives .
By End-User:The end-user segmentation includes hospitals and clinics, research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, direct-to-consumer (DTC) providers, and others. Hospitals and clinics are the primary end-users, as they directly utilize genomic testing and personalized medicine solutions to enhance patient care and treatment efficacy. Research institutions and pharmaceutical companies also play a vital role in advancing the field through clinical trials, drug development, and translational research. The increasing presence of DTC providers is expanding access to genomic services for consumers .
The UK Genomics & Personalized Medicine Market is characterized by a dynamic mix of regional and international players. Leading participants such as Illumina, Inc., Thermo Fisher Scientific Inc., Roche Holding AG, QIAGEN N.V., BGI Genomics Co., Ltd., Genomics England Limited, Oxford Nanopore Technologies plc, Congenica Ltd., Yourgene Health plc, Sano Genetics Ltd., Lifebit Biotech Ltd., 23andMe, Inc., Myriad Genetics, Inc., Guardant Health, Inc., GRAIL, Inc., Foundation Medicine, Inc., Personalis, Inc., Invitae Corporation, Ambry Genetics Corporation contribute to innovation, geographic expansion, and service delivery in this space.
The future of the UK genomics and personalized medicine market appears promising, driven by technological advancements and increasing consumer demand for tailored healthcare solutions. As genomic testing becomes more affordable and accessible, healthcare providers are expected to integrate these services into routine care. Additionally, the collaboration between public and private sectors will likely foster innovation, leading to the development of new therapies and improved patient outcomes, ultimately transforming the healthcare landscape in the UK.
| Segment | Sub-Segments |
|---|---|
| By Type | Diagnostic Testing (e.g., NGS, PCR, Microarray) Therapeutic Applications (e.g., Targeted Therapies, Gene Therapy) Research and Development Services (e.g., Genomic Data Analysis, Clinical Trial Support) Genetic Counseling Bioinformatics Solutions (e.g., Genomic Data Interpretation, AI-driven Analytics) Genomic Data Management (e.g., Cloud-based Platforms, Data Security Solutions) Pharmacogenomics Services Others |
| By End-User | Hospitals & Clinics Research Institutions Pharmaceutical & Biotechnology Companies Diagnostic Laboratories Academic Institutions Direct-to-Consumer (DTC) Providers Others |
| By Application | Oncology (Cancer Genomics, Liquid Biopsy) Rare & Inherited Diseases Cardiovascular Diseases Neurological Disorders Infectious Diseases (e.g., Pathogen Genomics, Antimicrobial Resistance) Reproductive Health (e.g., Preimplantation Genetic Diagnosis, Carrier Screening) Others |
| By Distribution Channel | Direct Sales Online Platforms Distributors Partnerships with Healthcare Providers Others |
| By Region | England Scotland Wales Northern Ireland Others |
| By Customer Type | B2B B2C Government Contracts Non-Profit Organizations Others |
| By Pricing Model | Subscription-Based Pay-Per-Use Bundled Services Value-Based Pricing Others |
| Scope Item/Segment | Sample Size | Target Respondent Profiles |
|---|---|---|
| Oncology Genomic Testing | 60 | Oncologists, Genetic Counselors |
| Pharmacogenomics Services | 50 | Pharmacists, Clinical Researchers |
| Direct-to-Consumer Genetic Testing | 45 | Marketing Managers, Product Development Leads |
| Rare Disease Genomics | 40 | Healthcare Providers, Patient Advocacy Leaders |
| Genomic Data Analysis Services | 40 | Bioinformaticians, Data Scientists |
The UK Genomics & Personalized Medicine Market is valued at approximately USD 9.1 billion, driven by advancements in genomic technologies, increased adoption of next-generation sequencing, and a focus on precision oncology and rare disease management.
What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.
